CHA Biotech sell stake in U.S. branch to focus on stem cell tereatment

[Gettyimages Bank]

SEOUL -- CHA Biotech, a biopharmaceutical company in South Korea, secured an additional fund of 54.3 billion won ($47 million) to speed up the development of stem cell treatments by selling off a controlling stake in its U.S. branch.

CHA Biotech said in a regulatory filing on Tuesday that it sold a 60 percent stake in Stem Cell & Regenerative Medicine International to Astellas Institute for Regenerative Medicine, a subsidiary of Astellas Pharma, an American company which develops stem cell therapies with a focus on diseases that cause blindness.

"Based on the country's largest stem cell pipeline, we will strive harder to advance the commercialization of our products," CHA Biotech CEO Oh Sang-hoon said. CHA Biotech's parent medical group established a cell therapy center in Tokyo in 2013.

Lim Chang-won cwlim34@ajunews.com

© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.

CHA Biotech sell stake in U.S. branch to focus on stem cell tereatment

Related News